師健友
一、 個(gè)人簡(jiǎn)介
2010年博士畢業(yè)于四川大學(xué)藥物化學(xué)專業(yè)。2013-2016年跟隨導(dǎo)師魏于全院士從事博士后研究。2010年7月至今在電子科技大學(xué)附屬醫(yī)院·四川省人民醫(yī)院任職，現(xiàn)為研究員、教授、碩博士研究生導(dǎo)師，美國(guó)北卡羅來納大學(xué)教堂山分校訪問學(xué)者（2016-2018），曾任四川省藥物流行病學(xué)專委會(huì)委員、四川省預(yù)防醫(yī)學(xué)會(huì)藥物應(yīng)用安全分委會(huì)委員、四川省國(guó)際醫(yī)學(xué)交流促進(jìn)會(huì)生物免疫治療專業(yè)委員會(huì)委員等，現(xiàn)任世界中醫(yī)藥聯(lián)合會(huì)道地藥材多維評(píng)價(jià)理事、中國(guó)化學(xué)快報(bào)青年編委、中國(guó)醫(yī)學(xué)生物技術(shù)協(xié)會(huì)納米生物技術(shù)分會(huì)委員，被評(píng)為第十三批四川省衛(wèi)生健康委員會(huì)學(xué)術(shù)與技術(shù)帶頭人、第十二批四川省學(xué)術(shù)與技術(shù)帶頭人后備人選、第十一批省衛(wèi)生計(jì)生委學(xué)術(shù)技術(shù)帶頭人后備人選。主要從事小分子藥物設(shè)計(jì)與新藥開發(fā)工作。作為項(xiàng)目負(fù)責(zé)人，先后承擔(dān)國(guó)家自然基金項(xiàng)目 2 項(xiàng)，中國(guó)博士后科研基金面上項(xiàng)目 1 項(xiàng)，國(guó)家中醫(yī)藥管理局臨床基地建設(shè)項(xiàng)目 1 項(xiàng)，四川省自然科學(xué)基金創(chuàng)新研究群體項(xiàng)目1項(xiàng)，四川省科技廳杰出青年基金培育項(xiàng)目 1 項(xiàng)，四川省科技廳青年科技創(chuàng)新研究團(tuán)隊(duì)項(xiàng)目1項(xiàng)，成都市科技局應(yīng)用基礎(chǔ)項(xiàng)目 1 項(xiàng)，電子科技大學(xué)中央高?；?1 項(xiàng)課題等。近 5 年，申請(qǐng)國(guó)家發(fā)明專利 9 項(xiàng)，獲得 6項(xiàng)國(guó)家發(fā)明專利授權(quán)，在STTT、JMC、CCL、EJMC 等藥學(xué)權(quán)威期刊雜志上發(fā)表多篇相關(guān)學(xué)術(shù)論文，其中第一（含并列）作者及通訊作者50余篇。
二、代表性成果（可含承擔(dān)項(xiàng)目、發(fā)表論文、論著、獲獎(jiǎng)等）
1.科研項(xiàng)目：
1.1 基于計(jì)算機(jī)輔助設(shè)計(jì)和SPR發(fā)現(xiàn)新穎的SKP2抑制劑及其抗腫瘤活性與機(jī)制研究，82073311，在研，56萬
1.2 個(gè)體化藥物治療小分子創(chuàng)新藥物四川省青年科技創(chuàng)新研究團(tuán)隊(duì)，2022JDTD0025，在研，40萬
1.3 結(jié)構(gòu)新穎的LSD1/GSK3β雙靶點(diǎn)小分子抑制劑的設(shè)計(jì)、合成與抗胃癌藥理學(xué)研究，2021LY021，在研，30萬
1.4 基于智能控制算法神經(jīng)網(wǎng)絡(luò)模型研究真空冷凍干燥川芎工藝，2021HX026，在研，10萬
1.5 基于計(jì)算機(jī)輔助的HDAC/Aurora雙靶點(diǎn) 抑制劑的設(shè)計(jì)、合成、活性篩選及機(jī)制研究，川干研2022-219，在研，5萬
2.發(fā)表論文
【1】Lu Haiying, Zhou Qiaodan, He Jun, Jiang Zhongliang, Peng Cheng*, Tong Rongsheng*, Shi Jianyou*, Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials [J], Signal Transduction and Targeted Therapy, 5(1), 213, 2020
【2】Peng Ting, Qi Baowen, He Jun, Ke Hengming*, Shi Jianyou*, Advances in the Development of Phosphodiesterase-4 Inhibitors [J], Journal of Medicinal Chemistry, 63(19): 10594-10617, 2020
【3】Qi Baowen, Zhong Ling, He Jun, Zhang Hongjia, Li Fengqiong, Wang Ting, Zou Jing, Lin Yao-Xin, Zhang Chengchen, Guo Xiaoqiang, Li Rui*, Shi Jianyou*, Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents [J], Journal of Medicinal Chemistry, 62(17): 7697-7707, 2019
【4】Hou Jun, Jiang Changqing, Wen Xudong, Li Chengming, Xiong Shiqiang, Yue Tian, Long Pan*, Shi Jianyou*, Zhang Zhen*, ACSL4 as a Potential Target and Biomarker for Anticancer: From Molecular Mechanisms to Clinical Therapeutics [J], Frontiers in Pharmacology, 13, 949863, 2022
【5】Liang Qi, Liu Maoyu, Li Jian, Tong Rongsheng, Hu Yonghe*, Bai Lan*, Shi Jianyou*, NAE modulators: A potential therapy for gastric carcinoma [J], European Journal of Medicinal Chemistry, 231, 114156, 2022
【6】Wu Xianbo, Xu Yihua, Liang Qi, Yang Xinwei, Huang Jianli, Wang Jie, Zhang Hong*, Shi Jianyou*, Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment [J], Frontiers in Pharmacology, 13, 875372, 2022
【7】Xin Ren, Jianyou Shi, Ruihuan Duan, Jun Di, Chao Xue, Xiao Luo, Qing Liu, Mengyang Xia?, Bo Lin?, Wu Tang?, Construction of high-efficiency CoS@Nb2O5 heterojunctions accelerating charge transfer for boosting photocatalytic hydrogen evolution [J], Chinese Chemical Letters, 33, 4700-4704, 2022
【8】Zhang Zhenzhen, Liu Xin, Zhao Liyun, Zhou Yaru, Shi Jianyou*, Chen Weini*, Li Jinqi*, A review on the treatment of multiple myeloma with small molecular agents in the past five years [J], European Journal of Medicinal Chemistry, 229, 114053, 2022
【9】Liang Qi, Wang Juelan, Zhao Liyun, Hou Jun*, Hu Yonghe*, Shi Jianyou*, Recent advances of dual FGFR inhibitors as a novel therapy for cancer [J], European Journal of Medicinal Chemistry, 214, 113205, 2021
【10】Wang Ting, Xu Kaiju, Zhao Liyun, Tong Rongsheng*, Xiong Liang*, Shi Jianyou*, Recent research and development of NDM-1 inhibitors [J], European Journal of Medicinal Chemistry, 223, 113667, 2021
【11】Zhao Jing, Hu Gang, Huang Yi, Huang Yingchun*, Wei Xin*, Shi Jianyou*, Polysaccharide conjugate vaccine: A kind of vaccine with great development potential [J], Chinese Chemical Letters, 32(4): 1331-1340, 2021
【12】Du Xingkai, Li Jian, Luo Xiaojiao, Li Rong, Li Feng, Zhang Yiwen, Shi Jianyou*, He Jun*, Structure-activity relationships of Wee1 inhibitors: A review [J], European Journal of Medicinal Chemistry, 203, 112524, 2020
【13】He Li, Su Qian, Bai Lan, Li Meifeng, Liu Juanru, Liu Xiaomei, Zhang Cunyan, Jiang Zhongliang, He Jun, Shi Jianyou*, Huang Shan*, Guo Li*, Recent research progress on natural small molecule bibenzyls and its derivatives in Dendrobium species [J], European Journal of Medicinal Chemistry, 204, 112530, 2020
【14】Wang Ting, Wang Yujue, Liu Li, Jiang Zhongliang, Li Xingxing, Tong Rongsheng, He Jun*, Shi Jianyou*, Research progress on sirtuins family members and cell senescence [J], European Journal of Medicinal Chemistry, 193, 112207, 2020
【15】Yuan Ting, Qi Baowen, Jiang Zhongliang, Dong Wenjuan, Zhong Lei, Bai Lan, Tong Rongsheng, Yu Jiying*, Shi Jianyou*, Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade [J], European Journal of Medicinal Chemistry, 178468-483, 2019
【16】Zhou Yanping, Jiang Zhongliang, Lu Haiying, Xu Zhuyu, Tong Rongsheng, Shi Jianyou*, Jia Guiqing*, Recent Advances of Natural Polyphenols Activators for Keap1-Nrf2 Signaling Pathway [J], Chemistry & Biodiversity, 16(11): 2019
3.獲獎(jiǎng)
3.1 2020年入選第一批“浣花英才計(jì)劃”學(xué)科骨干項(xiàng)目
3.2 四川省衛(wèi)生健康委員會(huì)第五期委（局）直屬單位高層次人才專題研修班優(yōu)秀學(xué)員。